News|Videos|November 16, 2026

Why Should Hospitals Track Bloodstream Infections Beyond CLABSI?

What can hospitals miss when they focus on CLABSI rates? The authors examine how broader surveillance of bloodstream infections could help link potentially preventable catheter-related infections to longer stays, higher costs, and discharge needs.

A growing body of evidence suggests that tracking central line-associated bloodstream infection (CLABSI) metrics, while important, may capture only part of the total hospital-onset bloodstream infection burden.1 Prior analyses have found that CLABSI events may account for about one in 5 hospital-onset bloodstream infections,2 raising important questions about what may be missed when hospitals focus primarily on CLABSI rates.

That broader context helps explain why new research on the consequences of catheter-related infections matters. A recent peer-reviewed study, funded by Solventum and published in Antimicrobial Stewardship & Healthcare Epidemiology, examined potentially preventable central catheter-related infections (PPCRIs) in US inpatient data from 2022 and 2023 and found PCCRIs were associated with markedly higher total cost of care, substantially longer length of stay, higher in-hospital mortality, and lower likelihood of discharge to home as compared to at-risk non-PCCRI cases. In other words, the issue is not only whether hospitals are seeing the full scope of bloodstream harm, but also whether they fully understand its downstream clinical and operational impact.

True Costs of PPCRIs

Largely preventable, CLABSIs remain among the most expensive hospital-acquired complications. 3 By analyzing inpatient data, the study found that the mean total cost of PPCRI cases was approximately $162,000 in 2022 and $187,000 in 2023, compared with $44,000 and $40,000 for non-PPCRI cases, respectively.

While the non-PPCRI had an increased average excess length of stay (LOS) (5 to 6 days), the average excess LOS for infected patients was much greater (38 to 44 days), and these potentially preventable infections drive up costs and significantly increase mortality rates. Much of the excess cost appears to stem from prolonged hospitalization rather than treatment expense alone.3 The study estimated that preventing a PPCRI could potentially reduce total care costs by approximately $100,000 per case.

While central lines receive the vast majority of surveillance attention, they represent only a fraction of total vascular access.4 Hospitals place roughly 400 million peripheral IV catheters (PIVCs) per year, versus 3 to 5 million central lines. One study found that 1.45% of patients with PIVCs experienced bloodstream infections (BSI).5 The same study found that patients with PIVC complications had increased inpatient length of stay and mean hospitalization cost and were less likely to be discharged home and more likely to have died.5 With BSI accounting for 82% of all PIVC-associated complications in this study, the findings suggest that the overall economic and health burdens of these infections are substantial even if they occur infrequently.

Unreported Operational Burdens

Viewing extended patient stays through an operational lens reveals how capacity constraints may impact an entire organization. Prolonged hospital stays may contribute to broader capacity and resource pressures across the facility.

The fallout of missing infections compounds long after hospitals stabilize infected patients. PPCRI patients are less likely to be discharged home and more likely to require postacute care than at-risk patients without PPCRI. Those downstream costs and care needs associated with PPCRIs may not be reflected in a hospital’s CLABSI rate, so the true economic burden of PPCRIs is likely underestimated.

Hospitals need to look no further than overtaxed bed occupancy, ongoing staffing pressure, and total cost of care. In our experience, systems fail to connect those factors back to their common and preventable bloodstream origins. We’ve also seen first-hand how organizations and patients are routinely impacted by this lapse in assessment and ongoing oversight. Together, these observations suggest that a narrow surveillance lens may limit a hospital’s ability to recognize the broader clinical and economic burden associated with bloodstream infections and identify opportunities for prevention.

Embracing a One Bloodstream Mindset

What are hospitals to do? Broaden focus. Capture more than CLABSI to reveal the full bloodstream harms picture. Focus on capturing all human harms—1 bloodstream—vs 1 hospital origination point.

Policymakers are already moving in this direction. A new measure under consideration by CMS would look beyond organism-specific approaches, such as MRSA Bacteremia Laboratory-Identified (LabID) event surveillance and device-associated approaches, such as CLABSI, and would include hospital-onset bacteremia and fungemia (HOB), which capture bloodstream harm regardless of device source. Infection prevention leaders are championing a concept of catheter-associated bloodstream infection (CABSI) to bridge the surveillance gap between central lines and peripheral vascular access devices.6 Hospital leaders who prepare now across all vascular devices may be better positioned as reporting expectations evolve.

What does a “One Bloodstream” mindset involve? For starters, broader surveillance. Identify hospital-onset bloodstream infections originating from sources other than central lines, including peripheral IV catheters. Prioritize hospital data collection that reflects all bloodstream infection risks, rather than a partial picture of harms.

Next, get serious about safety. Focus on the discipline surrounding every device. Apply the same insertion and maintenance bundle adherence you use for central lines to the devices you use most. Volume hides the most concentrated risks.

Finally, reframe the conversation. Our experience suggests that everyone benefits when hospitals elevate bloodstream protection as an organizational quality, capacity, and financial priority, not an isolated statistic. By connecting PPCRI prevention to patients’ length of stay and total cost of care, we believe it earns its place in strategic planning rather than sitting in a departmental silo.

Why Widen the Surveillance Lens?

For hospital leaders, the case for broader bloodstream surveillance is likely straightforward: What goes unmeasured goes unmanaged. Targeted prevention of PPCRIs may help organizations identify preventable harm earlier and reduce excess length or stay and total cost of care. The hospitals that act on the full picture of bloodstream infection risk and the economic burden of PPCRIs and CLABSI may be better positioned to improve outcomes, strengthen operations, and prepare for a changing measurement landscape.

References

1. Krishnan J, Gettler EB, Campbell M, et al. Comparative epidemiology of hospital-onset bloodstream infections (HOBSIs) and central line-associated bloodstream infections (CLABSIs) across a three-hospital health system. Infect Control Hosp Epidemiol. 2024;45(8):952-958. doi:10.1017/ice.2024.38.

2. Yu KC, Jung M, Ai C. Characteristics, costs, and outcomes associated with central-line-associated bloodstream infection and hospital-onset bacteremia and fungemia in US hospitals. Infect Control Hosp Epidemiol. 2023 Dec;44(12):1920-1926. doi: 10.1017/ice.2023.132.

3. Soloway L, Kärpänen T, Guy A. Increased cost of care and length of stay due to potentially preventable catheter-related infections in US inpatient data, 2022-2023. Antimicrob Steward Healthc Epidemiol. 2026 Jul 31;6(1):e232. doi: 10.1017/ash.2026.10801. PMID: 42553628

4. Marsh N, Larsen EN, Ullman AJ, et al. Peripheral intravenous catheter infection and failure: a systematic review and meta-analysis. Int J Nurs Stud. 2024;151:104673. doi:10.1016/j.ijnurstu.2023.104673

5. Lim S, Gangoli G, Adams E, et al. Increased Clinical and Economic Burden Associated With Peripheral Intravenous Catheter-Related Complications: Analysis of a US Hospital Discharge Database. Inquiry. 2019 Jan-Dec;56:46958019875562. doi: 10.1177/0046958019875562. PMID: 31524024

6. Guide to Preventing Catheter-Associated Bloodstream Infections in Adults. Association for Professionals in Infection Control and Epidemiology. Arlington, VA: APIC; 2025.


Related to this article